logo
 
The Union Health Ministry on Thursday rejected media reports that Covaxin manufacturer Bharat Biotech skipped certain processes and accelerated clinical trials due to political pressure, calling them "completely misleading, fallacious and ill-informed".

"The government of India and the national regulator Central Drugs Standard Control Organisation (CDSCO) have followed a scientific approach and prescribed norms in approving the Covid-19 vaccines for emergency use authorisation," the Ministry said.

The media reports had claimed that Bharat Biotech, manufacturer of the indigenous Covaxin, "had to skip certain processes" and "speed" up clinical trials due to political pressure.

They also



alleged that there were several irregularities in the three phases of the clinical trials.

The Ministry said that the Subject Expert Committee (SEC) of CDSCO met on January 1-2, 2021 and after due deliberations, made the recommendations in respect of proposal for Restricted Emergency Approval of the vaccine.

"Before Covaxin was approved for restricted emergency use in January 2021, the Subject Expert Committee reviewed the data on safety and immunogenicity of the vaccine and recommended for grant of permission for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains," it added.
No Comments For This Post, Be first to write a Comment.
Leave a Comment
Name:
Email:
Comment:
Enter the code shown:


Can't read the image? click here to refresh
etemaad live tv watch now

Todays Epaper

English Weekly

neerus indian ethnic wear
Latest Urdu News

Do you think AAP will perform better in Delhi polls without alliance?

Yes
No
Can't Say